Brief Title
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
Official Title
Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma
Brief Summary
This phase II trial studies how well neutron radiation therapy and pembrolizumab work in
treating participants with urothelial carcinoma that has spread to other places in the body.
Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving radiation therapy and pembrolizumab may work better than radiation alone in
treating participants with urothelial carcinoma that has spread to other places in the body.
Detailed Description
OUTLINE:
Participants receive pembrolizumab intravenously (IV) on days 1 and 22. On day 23,
participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron
radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43
and continue per standard of care in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, participants are followed up every 3 months.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Overall response rate per immune-modified response evaluation criteria in solid tumors
Secondary Outcome
Overall survival
Condition
Urothelial Carcinoma
Intervention
Laboratory Biomarker Analysis
Study Arms / Comparison Groups
Treatment (Pembrolizumab, neutron radiation therapy)
Description: Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
13
Start Date
January 17, 2019
Completion Date
May 1, 2024
Primary Completion Date
November 1, 2023
Eligibility Criteria
Inclusion Criteria:
- Pathologically proven (either histologic or cytologic) diagnosis of urothelial
carcinoma
- At least two sites of disease that are measurable by Response Evaluation Criteria in
Solid Tumors (RECIST) 1.1 criteria
- Eligible for checkpoint inhibitor immunotherapy (pembrolizumab) per standard of care
- No history of autoimmune disease requiring systemic therapy (e.g. steroids or biologic
agents)
- Absolute neutrophil count (ANC) ≥ 1500 /mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin > 9 g/dL
- Creatinine ≤ 1.5 x upper limit of normal (ULN) OR ≥ 60 mL/min
- Total bilirubin ≤ 1.5 ULN OR direct bilirubin ≤ ULN if total bilirubin > 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN OR < 5
x ULN if patient has liver metastasis
- Albumin >= 2.5 g/dL
- International normalized ratio (INR) or PT ≤ 1.5 x ULN unless on anticoagulation
therapy, in which case prothrombin time (PT) or partial thromboplastin time (PTT)
should be in the therapeutic range
- PTT ≤ 1.5 x ULN unless on anticoagulation therapy, in which case PT or PTT should be
in the therapeutic range
- Eligible for neutron radiation treatment to 1-3 sites of metastatic disease (lesions
do not have to be symptomatic)
- No steroids for at least 2 weeks prior to enrollment, and patient must not be expected
to require steroids during the study period
- Zubrod performance status 0-2
- Patient must sign study specific informed consent prior to study entry
- Patients who are sexually active must use medically acceptable forms of contraception
- Life expectancy must be > 3 months
Exclusion Criteria:
- Has a known history of active TB (Bacillus tuberculosis)
- Hypersensitivity to pembrolizumab or any of its excipients
- Has a known additional malignancy that is progressing or requires active treatment
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
- Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
- Has known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg]
reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]
[qualitative] is detected)
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator
- Has known history of, or any evidence of active, non-infectious pneumonitis
- Has an active infection requiring systemic therapy
- Has received a live vaccine within 30 days of planned start of study therapy
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis; subjects with previously treated brain metastases may participate provided
there is no evidence of new or enlarging brain metastases, and are not using steroids
for at least 7 days prior to trial treatment; this exception does not include
carcinomatous meningitis which is excluded regardless of clinical stability
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jing Zeng, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT03486197
Organization ID
9940
Secondary IDs
NCI-2018-00412
Responsible Party
Sponsor
Study Sponsor
University of Washington
Study Sponsor
Jing Zeng, Principal Investigator, Fred Hutch/University of Washington Cancer Consortium
Verification Date
February 2023